In a report released today, Asthika Goonewardene from Truist Financial maintained a Buy rating on BioNTech SE (BNTX – Research Report), with a price target of $151.00.
Asthika Goonewardene’s rating is based on several key considerations. Despite BioNTech SE’s fourth-quarter 2024 revenues exceeding expectations, the company’s guidance for fiscal year 2025 suggests a notable decrease in revenue projections. This is primarily due to anticipated inventory write-downs and potential market challenges, such as price erosion from new competitors and possible shifts in contracted purchases by the EU. However, Goonewardene believes these headwinds may be temporary, with the potential for recovery in subsequent years.
Moreover, BioNTech’s ongoing developments in its pipeline, particularly the expected pivotal data for BNT327 and BNT323 in 2025, are seen as transformative opportunities that could drive future growth. While there are risks, such as potential disruptions from vaccine opposition, the analyst remains optimistic about BioNTech’s strategic positioning and long-term prospects, leading to the Buy rating.
Goonewardene covers the Healthcare sector, focusing on stocks such as Exelixis, BioNTech SE, and Iovance Biotherapeutics. According to TipRanks, Goonewardene has an average return of -15.0% and a 25.25% success rate on recommended stocks.
In another report released today, BMO Capital also maintained a Buy rating on the stock with a $143.00 price target.